Negative symptoms as key features of depression among cannabis users. A preliminary report by Bersani, Giuseppe et al.
European Review for Medical and Pharmacological Sciences
547
Abstract. – OBJECTIVE: Cannabis use is
frequent among depressed patients and may
lead to the so-called “amotivational syndrome”,
which combines symptoms of affective flatten-
ing and loss of emotional reactivity (i.e. the so-
called “negative” symptomatology). The aim of
this study was to investigate the negative
symptomatology in depressed patients with
concomitant cannabis use disorders (CUDs) in
comparison with depressed patients without
CUDs.
PATIENTS AND METHODS: Fifty-one pa-
tients with a diagnosis of Major Depressive Dis-
order (MDD) and concomitant CUD and fifty-
one MDD patients were enrolled in the study.
The 21-Item Hamilton Depression Rating Scale
(HDRS) and the negative symptoms subscales
of the Positive and Negative Syndrome Scale
(PANSS) were used to assess depressive and
negative symptomatology.
RESULTS: Patients with cannabis use disor-
ders presented significantly more severe nega-
tive symptoms in comparison with patients
without cannabis use (15.18 ± 2.25 vs 13.75 ±
2.44; t100 = 3.25 p = 0.002).
DISCUSSION: A deeper knowledge of the
“negative” psychopathological profile of MDD
patients who use cannabis may lead to novel
etiopathogenetic models of MDD and to more
appropriate treatment approaches.
Key Words:
Cannabis use disorders, Major depressive disorder,
Amotivational syndrome, Negative symptoms.
Introduction
Cannabis is the most widely used illegal psy-
choactive substance in the world and the lifetime
prevalence estimates of cannabis use are in the
Negative symptoms as key features of 
depression among cannabis users: 
a preliminary report
G. BERSANI1, F.S. BERSANI1,2,4, E. CAROTI1, P. RUSSO1, G. ALBANO1, 
G. VALERIANI1,2,4, C. IMPERATORI3, A. MINICHINO2, G. MANUALI1, O. CORAZZA4
1Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy
2Department of Neurology and Psychiatry, Sapienza University of Rome, Rome, Italy
3Department of Human Sciences, European University of Rome, Italy
4School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Hertfordshire, UK
Corresponding Author: Francesco Saverio Bersani, MD; e-mail: bersani.fs@gmail.com
range of 10-30% of the adult population1. A link
between cannabis use and psychosis has been ob-
served in several studies: long-term cannabis use
increases the risk of psychosis in individuals
with certain genetic or environmental vulnerabil-
ities including genetic liability, childhood trauma
and urban upbringing2. However, while extensive
attention has been given to the links between
cannabis use and psychotic outcomes3-5, the
causal relationship with other psychiatric disor-
ders and especially with depressive disorders still
remains debated6-9.
In recent years concerns emerged on the rates
of cannabis use associated with depression
among young people in many countries10-13.
Moreover, increasing occurrence of suicide pro-
vokes public health concerns over the possible
contribution of cannabis use to its etiology14.
Empirical literature reports that use of cannabis
among the general adult population is 8%15,
while cannabis use among subjects with depres-
sive symptoms ranges from 17% to 40%15-17. Re-
searchers have observed cross-sectional associa-
tions between cannabis use and a higher likeli-
hood of depressive symptoms18,19. Longitudinal
studies suggested that weekly cannabis use in-
creases the risk of depression in young adult-
hood20,21, but there are contrasting results on the
topic22,23. The inconsistency of several findings
across the different studies may be related to the
use of different measures of cannabis use, as well
as affective outcomes and inadequate considera-
tion of confounding features. Risk factors for de-
pression, in fact, include exposure to adverse life
events, comorbidity with other psychopathologi-
cal conditions (e.g. anxiety or sleep disorders,
psychotic symptoms), socio-economic adversity,
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Central Nervous System active drugs (excluding
cannabis) in the two weeks before the study.
Measures
All the patients were administered the 21-Item
Hamilton Depression Rating Scale (HAM-D)34
and the negative symptoms subscale of the Posi-
tive and Negative Syndrome Scale (PANSS)35.
The HAM-D is a 21-item scale, but only the first
17 items are added to obtain the total score; sin-
gle items are rated on a Likert scale, with 8 items
ranging 0 (symptom is not present) to 4 (symp-
tom is severe) and 9 items ranging 0-2. Scores
are interpreted as follows: 0-7 is considered to be
within normal range, 8-13 indicates mild depres-
sion, 14-18 indicates moderate depression, 19-22
indicates severe depression, and ≥23 indicates
very severe depression34. The PANSS is a 30-
item clinician-rated symptom severity measure
that was originally developed to assess three
clusters symptoms of schizophrenia: positive
symptoms (7 items), negative symptoms (7
items), and general psychopathology (16
items)35. All items are rated on a 7-point Likert
scale ranging from 1 (absent) to 7 (extreme
severity). Although PANSS is widely used in
schizophrenic research, it is also applied to MDD
and other psychiatric patients36-39. Several studies
reported good psychometric properties of
PANSS40-42 also in MDD patients37. In the pre-
sent study the negative symptoms subscales of
PANSS were used.
Statistical Analysis
Differences between groups (MDD/CUDs vs.
MDD) were analyzed with t-tests for dimension-
al variables, and one-way Fisher exact tests for
2*2 contingency tables. In order to avoid family-
wise type-I errors, a formal Bonferroni correc-
tion was applied by dividing the limit of signifi-
cance by the number of comparisons (p =
0.05/5= 0.01). All the analyses were performed
with the Statistical Package for the Social Sci-
ences (SPSS) 19.0 for Windows (IBM Corpora-
tion, Armonk, NY, USA). p < 0.05 was consid-
ered statistically significant.
Results
Differences between groups (MDD/CUDs vs.
MDD) are given in Table I. There were no sig-
nificant differences between groups for socio-de-
mographic variables and in depression severity.
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substance use and problematic peer relation-
ships24,25; since these factors are also associated
with cannabis use26, controlling for them is im-
portant.
To summarize, it is a reasonable hypothesis
that low-level cannabis use is not associated with
an increased risk of affective disorders, while
heavy cannabis use (at least weekly use) in ado-
lescence can facilitate later development of ma-
jor depressive disorder. From a psychopathologi-
cal point of view, it is known that cannabis use
may lead to the so-called “amotivational syn-
drome”27 that combines symptoms of affective
flattening and loss of emotional reactivity, large-
ly similar to the so-called “negative” symptoms
of schizophrenia28. Although initially considered
specific to schizophrenia, in fact, “negative”
symptoms have subsequently been described as
prominent features of other neurological and psy-
chiatric disorders including depression29, Parkin-
son’s disease30, Alzheimer’s disease31 and epilep-
sy32. Despite the frequent occurrence of cannabis
use among depressed patients, no studies to date
have investigated the characteristics of “nega-
tive” symptoms in depressed patients with con-
comitant cannabis use disorders (CUDs). Given
the information outlined above, the aim of the
present study was to perform a dimensional de-
scription of negative symptoms in MDD patients
with concomitant CUDs in comparison with
MDD patients without CUDs.
Patients and Methods
Participants
The sample consisted of fifty-one unmedicated
patients with a diagnosis of MDD/CUDs (37
males and 14 females aged 18 to 46 years [mean
age: 28.29±8.02]) and fifty-one unmedicated pa-
tients with a diagnosis of MDD (33 males and 18
females, aged 18 to 46 years [mean age:
30.90±8.70]) referring at the A. Fiorini Universi-
ty Hospital of Terracina, Sapienza University of
Rome, Italy.
After signing a written informed consent form,
patients underwent a structured clinical interview
according to the Structured Clinical Interview for
DSM IV Disorders (SCID-I-IV) [33]. Patients
were included if they had a diagnosis of
MDD/CUDs or MDD and if they were 18 years
or older. Patients were excluded for any of the
following reasons: history of medical, neurologic
diseases; other Axis I diagnosis; assumption of
MDD patients MDD patients
with CUDs without CUDs t-tests
Variables (N = 51) (N = 51) (DF = 100) p
Age – M (SD) 28.29 ± 8.02 30.90 ± 8.70 -1.57 0.12
Education: 13+ years, % 80.4 % 88.2% 0.42a
Men, % 72.5 % 64.7 % 0.52a
HAM-D – M (SD) 25.12 ± 4.85 24.01 ± 5.29 1.12 0.27
PANSS-negative symptoms scale 15.18 ± 2.25 13.75 ± 2.44 3.25 0.002
Table I. Bivariate analyses.
SD = standard deviation; DF = degrees of freedom; HAM-D = Hamilton Depression Rating Scale
PANSS = Positive and Negative Syndrome scale; MDD = Major depressive disorder; CUDs = Cannabis Use Disorders
aFischer’s Exact Test two-tailed
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while in the amygdala, hippocampus, basal gan-
glia and cerebellum they are expressed on both
GABAergic and pyramidal neurons46,47. The loca-
tion and function of the endogenous cannabinoid
system suggest that it may play a role in regulat-
ing the neuronal circuits involved in cognitive
function, emotions, and activity in the mesolimbic
reward contingency pathways48,49. Therefore, the
negative symptoms observed in MDD\CUDs pa-
tients could be attributed to the effect of Δ(9)THC
on these neural pathways.
From a clinical point of view, a deeper knowl-
edge of the “negative” psychopathological pro-
file of MDD patients who use cannabis may lead
to more appropriate treatment approaches. Med-
ications targeting the dopaminergic system, i.e.
bupropion50 or methylphenidate51, could be use-
ful in MDD patients with concomitant CUDs, as
well as other approaches with proven efficacy on
negative symptoms such as neurofeedback52 or
brain modulation techniques53,54. 
Conclusion
The effect of exogenous cannabinoids on psy-
chiatric disease is complex and largely unknown,
and further research is needed. The recent spread
of novel synthetic forms of cannabis55,56 and of
cannabis-based forms of medications57 give fur-
ther relevance to this issue.
––––––––––
Disclosure
This publication arises from collaborative activities and
staff exchanges among the collaborating institutions funded
by the European Commission (Erasmus Project). All au-
Compared to patients without CUDs, MDD pa-
tients with CUDs had higher mean scores on the
PANSS negative symptoms scale (15.18 ± 2.25
vs 13.75 ± 2.44; t100 = 3.25 p = 0.002).
Discussion
The results of the present study indicate that pa-
tients with cannabis use disorders present signifi-
cantly more severe “negative” symptoms (i.e.
blunted affect, emotional withdrawal, poor rap-
port, passive/apathetic social withdrawal, difficul-
ty in abstract thinking, lack of spontaneity/flow of
conversation, stereotyped thinking) in comparison
with patients without cannabis use. These out-
comes support previous findings indicating that
“negative” symptoms are prominent features of
depression29 and indicate that depressed patients
who are also cannabis users experience signifi-
cantly worse emotional, affective, cognitive and
social withdrawal than non-users.
Over the last two decades, cannabinoid research
has progressed. A major breakthrough has been the
discovery of a multifaceted endogenous cannabi-
noid system, a neuromodulatory system comprised
of (i) cannabinoid receptors, among which the sub-
type 1 (CB1) is the most abundant in the brain; (ii)
endogenous ligands for cannabinoid receptors, like
anandamide and 2-arachidonylglycerol; (iii) a pu-
tative membrane transporter; and (iv) enzymes in-
volved in the synthesis and inactivation of the en-
dogenous ligands43-45. The CB1 receptor was ini-
tially identified as the neuronal target of Δ(9)-
tetrahydrocannabinol (THC), the major psychoac-
tive ingredient of cannabis.
Neocortical CB1 receptors are expressed main-
ly on γ-aminobutyric acid (GABA) interneurons,
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